The fluorescence polarization immunoassay developed to detect and quantify antibodies against SARS-CoV-2 (image)

Hokkaido University

Caption

The fluorescence polarization immunoassay developed to detect and quantify antibodies against SARS-CoV-2. If present in a serum sample, antibodies against the SARS-CoV-2 virus will bind to fluorescently-labelled recombinant SARS-CoV-2 spike proteins (F-RBD); the antibody-bound proteins emit polarized light, which is measured by a fluorescence polarization analyzer (Keine Nishiyama, et al. Biosensors and Bioelectronics. June 5, 2021).

Credit

Keine Nishiyama, et al. Biosensors and Bioelectronics. June 5, 2021

Usage Restrictions

This image is copyrighted but may be used to report this press release, if credited as instructed.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.